UK Biosimilars Market Analysis Report 2022 to 2030

UK Biosimilars Market Analysis

$ 3999

The UK biosimilars market size was valued at $0.5 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 20.2% from 2022 to 2030 and will reach $2.1 Bn in 2030. The market is segmented by product type and indication type. The UK Biosimilars market will grow as Biosimilars provide a more affordable alternative to pricey biologic drugs, which can help to reduce healthcare costs for both patients and payers. The key market players are Pfizer, Sandoz, Celltrion, Biogen, Samsung Bioepis, Mylan, and others.

ID: IN10GBPH027 CATEGORY: Pharmaceuticals GEOGRAPHY: UK AUTHOR: Chandani Patel

Buy Now

UK Biosimilars Market Executive Summary

The UK biosimilars market size was valued at $0.5 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 20.2% from 2022 to 2030 and will reach $2.1 Bn in 2030. Due to a number of causes, including the expiration of biologic medication patents, rising healthcare costs, and government attempts to promote the use of biosimilars, the UK biosimilar industry has been expanding significantly in recent years. Because they provide a more affordable alternative to their reference products, biosimilars are playing a bigger role in the UK healthcare system.

The market is also confronted with difficulties including complicated regulatory requirements, expensive development and manufacturing costs, low patient and healthcare provider knowledge and acceptability, and competition from novel biologic therapies. However, the UK government is taking steps to encourage the use of biosimilars, including offering training and awareness campaigns for patients and healthcare professionals. Oncology, rheumatology, and gastroenterology are the top three therapeutic fields for biosimilars in the UK. In the UK, the National Health Service (NHS) is the primary payer for biosimilars, and the National Institute for Health and Care Excellence (NICE) oversees reimbursement through the Health Technology Assessment (HTA) procedure.

As more biologic medications lose their patent protection and biosimilar producers continue to develop and enhance their products, the UK biosimilar industry is anticipated to expand. Additionally, anticipated to fuel market expansion in the upcoming years are the government's continued efforts to encourage the usage of biosimilars.

UK biosimilars market analysis

Market Dynamics

Market Growth Drivers

Biosimilars provide a more affordable alternative to pricey biologic drugs, which can help to reduce healthcare costs for both patients and payers. Furthermore, makers of biosimilars will have the possibility to enter the market and provide less costly replacements once the patents on the reference biologic drugs expire.

Market Restraints

As businesses deal with legal and regulatory challenges, producing biosimilars and getting them authorized might be a challenging and drawn-out process. Additionally, medical professionals and patients may encounter significant resistance while utilizing biosimilars because of their lack of familiarity with these medications.

Additionally, there may be market obstacles that prohibit biosimilars from capturing a sizable portion of the market, such as exclusivity agreements between payers and the producers of reference medications.

Competitive Landscape

Key Players

Pfizer
Sandoz
Celltrion
Biogen
Samsung Bioepis
Mylan
Amgen
Teva
Fresenius Kabi
Accord Healthcare

Healthcare Policies and Regulatory Landscape

The regulation of biosimilars in the UK is overseen by the Medicines and Healthcare Products Regulatory Agency (MHRA). Biosimilars must demonstrate that they have similar quality, safety, and efficacy to the reference product through a rigorous regulatory process that includes analytical, non-clinical, and clinical studies.

The reimbursement of biosimilars in the UK is managed by the National Institute for Health and Care Excellence (NICE) through the Health Technology Assessment (HTA) process. NICE evaluates the clinical and cost-effectiveness of new drugs, including biosimilars, to determine whether they should be reimbursed by the National Health Service (NHS).

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

UK Biosimilars Market Segmentation

By Product

The monoclonal antibodies, insulin, granulocyte colony-stimulating factor, erythropoietin, recombinant human growth hormone, etanercept, follitropin, teriparatide, interferons, enoxaparin sodium, glucagon, and calcitonin are among the product categories that make up the biosimilars market. Monoclonal antibodies held a sizable portion of the market in 2020. The market is being driven by elements including the widespread use of monoclonal antibodies in the treatment of autoimmune diseases, cancer, and osteoporosis, as well as the affordability of such treatments.

Monoclonal Antibodies
- Infliximab
- Trastuzumab
- Rituximab
- Adalimumab
- Other monoclonal antibodies (bevacizumab, cetuximab, ranibizumab, denosumab, and eculizumab)
Insulin
Granulocyte Colony-Stimulating Factor
Erythropoietin
Recombinant Human Growth Hormone
Etanercept
Follitropin
Teriparatide
Interferons
Enoxaparin Sodium
Glucagon
Calcitonin

By Indication

The biosimilars market is divided into oncology, autoimmune and inflammatory diseases, chronic illnesses, blood disorders, growth hormone insufficiency, infectious diseases, and other indications based on the indication (infertility, hypoglycemia, myocardial infarction, postmenopausal osteoporosis, chronic kidney failure, and ophthalmic diseases). The market's largest sector in 2020 will be oncology. This market is expanding as a result of elements like the reduced cost of biosimilars compared to novel biologics and the increased incidence and prevalence of cancer.

Oncology
Inflammatory & Autoimmune Disorders
Chronic Diseases
Blood Disorders
Growth Hormone Deficiency
Infectious Diseases
Other Indications (infertility, hypoglycemia, postmenopausal osteoporosis, chronic kidney failure, and ophthalmic diseases)

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.